<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996827</url>
  </required_header>
  <id_info>
    <org_study_id>INST 0815</org_study_id>
    <nct_id>NCT00996827</nct_id>
  </id_info>
  <brief_title>Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma</brief_title>
  <official_title>Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Mexico Cancer Care Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Mexico Cancer Care Alliance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to understand differences in the serum vitamin D levels and immune status&#xD;
      in cutaneous malignant melanoma patients with different UV exposure histories in New Mexico.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well established that ultraviolet radiation (UV) exposure is related to the development&#xD;
      of melanoma. There is also evidence that immune reactions are altered after UV exposure in&#xD;
      the skin (locally) and perhaps throughout the body (systemically). Additionally, while the&#xD;
      role of vitamin D and melanoma development has not been fully established, UV-B exposure is&#xD;
      essential for vitamin D production in the skin. Increased sun exposure is also related to the&#xD;
      presence of solar elastosis, which might protect (1) or improve survival from melanoma. Thus,&#xD;
      melanoma represents a unique model for studying UV exposure, the immune system, and vitamin&#xD;
      D. Malignant melanoma is an antigenic cancer; therefore, the role of UV exposure-induced&#xD;
      immunosuppression and vitamin D production in the recognition, destruction and growth&#xD;
      inhibition of cancerous melanocytes is worth further study.&#xD;
&#xD;
      To underscore the importance of this project, the Scientific Advisory Committee of the&#xD;
      Melanoma Research Foundation and the Steering Committee of the Society of Melanoma Research&#xD;
      have indicated a need to collect more human data on the host immune response mechanisms in&#xD;
      melanoma and also to focus on the skin as a whole microenvironment, moving away from only in&#xD;
      vitro experiments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sufficient samples collected when 73% of target enrollment was reached.&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>• Evaluate serum 25(OH)-vitamin D concentrations. • Detect the presence of solar elastosis and local immunosuppression in skin biopsy samples • Assess the role of the systemic humoral immune response</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Evaluate cellular immunological changes of peripheral lymphocyte subpopulations • Sequence chromosome 6 from blood DNA samples of the patients</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Serum samples will be collected to evaluate the immune status of these patients.&#xD;
&#xD;
        -  Serum cytokine profiles&#xD;
&#xD;
        -  Whole blood samples - lymphocyte sub-populations from fresh, refrigerated whole blood&#xD;
           samples. Whole blood samples will be used to extract DNA and RNA material. The remaining&#xD;
           DNA for future research related to cytokine gene and vitamin D receptor single&#xD;
           nucleotide polymorphisms studies of the Molecular Epidemiology Laboratory&#xD;
&#xD;
        -  H &amp; E slides will be evaluated by our collaborating pathologist to validate diagnoses&#xD;
           and Breslow thickness&#xD;
&#xD;
        -  Formalin-fixed paraffin embedded blocks will be sectioned and stained for&#xD;
           immunohistochemistry&#xD;
&#xD;
        -  One slide will be prepared from the skin block to evaluate the presence of solar&#xD;
           elastosis in relation to UV exposure&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have recieved interferon or IL-2 therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resident of New Mexico&#xD;
&#xD;
          -  Age between the 1 and 95&#xD;
&#xD;
          -  Newly diagnosed with cutaneous invasive melanoma; any stage permitted (ICDO C44.0-9)&#xD;
             between September 1, 2008 and December 31, 2011.&#xD;
&#xD;
          -  SSM (superficial spreading melanoma) and NM (nodular melanoma) histological subtypes&#xD;
             are allowed&#xD;
&#xD;
          -  Access to a telephone or be able to participate in a personal interview at the clinic&#xD;
&#xD;
          -  Physically and mentally competent to complete a 1-hour telephone or personal interview&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular melanoma, LMM (lentigo maligna melanoma) or ALM (acral lentigo melanoma), and&#xD;
             mucosal melanoma cases.&#xD;
&#xD;
          -  No access to a telephone or is not able to meet with the interviewer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Montasur Shaheen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Berwick, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lovelace Women's Hospial</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.unm.edu</url>
    <description>University of New Mexico Cancer Center</description>
  </link>
  <link>
    <url>http://www.nmcca.org</url>
    <description>New Mexico Cancer Care Alliance</description>
  </link>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Skin cancer</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D receptor</keyword>
  <keyword>Sunlight</keyword>
  <keyword>Cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

